{"entity":{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","aka":["Haihe Biopharma Co., Ltd."],"tldr":"Haihe Biopharma is a China-based biotechnology company running 4 late-stage cancer trials of HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma and sarcomas.","summary":"Haihe Biopharma, based in Shanghai, China, is a biotechnology company. Haihe Biopharma (Shanghai Haihe Pharmaceuticals) is a China-based biopharmaceutical company focused on the discovery, development, production and commercialisation of innovative drugs, including several oncology candidates. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma, sarcomas, peripheral T-cell lymphomas and hodgkin lymphoma. The largest, NCT04390737 (Evaluate the Safety and Clinical Activity of HH2853), plans to enrol 254 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.haihepharma.com"},{"label":"ClinicalTrials.gov: trials led by Haihe Biopharma","url":"https://clinicaltrials.gov/search?lead=Haihe%20Biopharma%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","follicular-lymphoma","sarcoma","peripheral-t-cell-lymphoma","hodgkin-lymphoma","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["cyh33"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06909877","nct04390737","nct04270591"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.haihepharma.com","founded":2011,"stage":"growth","investors":[],"funding":[]},"route":"/companies/haihe-biopharma/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/"},{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/"}],"trial":[{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","route":"/trials/nct05043922/"},{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","route":"/trials/nct04270591/"},{"id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/"},{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/"}]}}